Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma, originating from mature B-cells in the lymph nodes or extranodal sites. It accounts for 30-40% of all non-Hodgkin lymphoma diagnoses globally, according to the American Cancer Society and the National Cancer Institute.
DLBCL develops when B-cells grow uncontrollably and form tumors that infiltrate lymph nodes, bone marrow, or organs such as the spleen or gastrointestinal tract. The term "diffuse" means the cancer cells are spread throughout the tissue rather than forming distinct nodules. "Large" refers to the size of the malignant cells under a microscope-typically larger than normal lymphocytes.
Diagnosis relies on biopsy analysis, immunohistochemistry staining, and molecular testing. Common markers include CD20, CD79a, and PAX5, which confirm B-cell origin. The presence of MYC, BCL2, or BCL6 rearrangements may indicate high-risk disease, including double-hit or triple-hit lymphomas.
Normal B-cells produce antibodies to fight infection. In DLBCL, genetic mutations disrupt cell cycle control and apoptosis pathways. Key mutations involve BCL6, BCL2, and MYC oncogenes. These alterations allow cells to proliferate indefinitely and resist programmed cell death.
For example, a translocation between chromosomes 8 and 14-t(8;14)-leads to overexpression of MYC, a protein that drives rapid cell division. This genetic event occurs in approximately 10-15% of DLBCL cases and correlates with poorer outcomes when combined with BCL2 overexpression.
Imaging studies such as PET-CT scans detect metabolic activity in tumor sites. A standardized uptake value (SUVmax) above 10 often indicates active disease. Response to therapy is assessed using the Lugano classification, which defines complete remission based on absence of metabolically active lesions.
DLBCL is classified into several subtypes based on gene expression profiles and cellular origins. The two main categories are germinal center B-cell-like (GCB) and activated B-cell-like (ABC), identified through gene expression profiling.
| Subtype | Origin | Prevalence | Prognosis | Treatment Implication |
|---|---|---|---|---|
| GCB | Germinally centered B-cells | ~50% | Better response to R-CHOP | More likely to achieve long-term remission |
| ABC | Activated B-cells | ~40% | Poorer survival without targeted therapy | May benefit from BTK inhibitors like ibrutinib |
| Primary mediastinal | Thymic B-cells | ~5% | Often presents in young adults | High cure rate with dose-adjusted EPOCH-R |
A non-obvious distinction: GCB and ABC subtypes respond differently to standard chemotherapy. GCB patients have a 70-80% five-year survival rate with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), while ABC patients show lower response rates due to constitutive activation of NF-κB signaling.
Double-hit lymphoma-defined by concurrent translocations involving MYC and BCL2 or BCL6-is a rare but aggressive variant. It occurs in 5-10% of DLBCL cases and has a median survival of less than 2 years without intensive therapy. Detection requires FISH testing, not routine histology.
DLBCL is sometimes mistaken for Hodgkin lymphoma because both affect lymph nodes and cause systemic symptoms like fever, night sweats, and weight loss. However, Hodgkin lymphoma features Reed-Sternberg cells, which are absent in DLBCL.
Another confusion arises with chronic lymphocytic leukemia (CLL), which also involves B-cells. But CLL progresses slowly and affects older adults, whereas DLBCL is rapidly growing and typically diagnosed in people aged 50-70.
Some patients assume all lymphomas are curable. While 60-70% of DLBCL patients achieve remission with first-line treatment, relapse occurs in 30-40% within five years. Patients who relapse or are refractory to initial therapy face reduced survival chances unless they receive newer treatments like CAR T-cell therapy.
A 62-year-old man presented with a 5 cm mass in his left neck, persistent fatigue, and unexplained fevers. CT scan revealed enlarged cervical and axillary lymph nodes. A biopsy showed sheets of large, pleomorphic B-cells positive for CD20, CD79a, and PAX5. FISH testing confirmed a t(8;14) translocation and BCL2 overexpression.
Based on the International Prognostic Index (IPI), he had a high-risk score due to advanced stage, elevated lactate dehydrogenase (LDH), and age over 60. He was treated with six cycles of R-CHOP. After four cycles, PET-CT showed partial response. He completed treatment and remains in remission at 24 months.
This case illustrates that even high-risk DLBCL can be managed effectively with timely diagnosis and aggressive therapy. Early detection improves outcomes-median survival drops to 18 months if treatment is delayed beyond four weeks after diagnosis.
Symptoms such as painless swelling in lymph nodes, unexplained weight loss (>10% body weight in six months), persistent fevers, or night sweats warrant immediate evaluation. A biopsy is required for definitive diagnosis. Blood tests including LDH, beta-2 microglobulin, and complete blood count support staging.
After diagnosis, patients undergo imaging to determine disease extent. Staging ranges from I (localized) to IV (widespread). Treatment depends on risk stratification. Standard first-line therapy is R-CHOP every 21 days for six cycles. Response is monitored via PET-CT after two cycles.
If the disease progresses or recurs, options include high-dose chemotherapy followed by autologous stem cell transplant, or newer agents like polatuzumab vedotin, lenalidomide, or CAR T-cell therapy. A recent trial reported a 50% response rate in relapsed DLBCL patients treated with axicabtagene ciloleucel (Yescarta).
I've seen a patient with primary CNS DLBCL survive over three years after receiving intrathecal methotrexate and whole-brain radiation. The disease is rare-only 1-2% of cases-but treatable with specialized protocols.
These terms inform clinical workflows but don't define the disease itself. DLBCL remains a distinct entity with specific diagnostic criteria and treatment algorithms.
Early diagnosis and tailored therapy improve survival. With current standards, 60-70% of patients achieve durable remission. Advances in genomics and immunotherapy continue to refine outcomes, particularly for high-risk subtypes.